Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage

INTERPACE BIOSCIENCES, INC.

Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.
Board approved restructuring plan Jan 14, 2025 due to CMS ending PancraGEN coverage (announced Jan 9, 2025).
Workforce reduction; severance costs estimated $0.8M–$1.0M, primarily recorded in Q1 2025.
Expected annual cost savings of $12.5M–$14.5M, expected to offset approximately one-third of revenue loss from PancraGEN.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.